Clinical Trial Update: A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nilotinib in adults with imatinib-resistant or intolerant chronic myeloid leukemia across blast crisis, accelerated phase, or chronic p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia | Phase 3 | Status: COMPLETED